SCI Pharmtech, Inc. (TPE:4119)
52.00
-0.30 (-0.57%)
Aug 19, 2026, 1:30 PM CST
SCI Pharmtech Revenue
SCI Pharmtech had revenue of 272.87M TWD in the quarter ending June 30, 2026, a decrease of -26.55%. This brings the company's revenue in the last twelve months to 1.26B, down -18.83% year-over-year. In the year 2025, SCI Pharmtech had annual revenue of 1.34B, down -11.81%.
Revenue (ttm)
1.26B
Revenue Growth
-18.83%
P/S Ratio
4.93
Revenue / Employee
5.27M
Employees
239
Market Cap
6.21B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.34B | -180.02M | -11.81% |
| Dec 31, 2024 | 1.52B | 319.58M | 26.54% |
| Dec 31, 2023 | 1.20B | 304.42M | 33.83% |
| Dec 31, 2022 | 899.74M | 35.52M | 4.11% |
| Dec 31, 2021 | 864.22M | -1.83B | -67.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Standard Chemical & Pharmaceutical | 7.08B |
| Formosa Laboratories | 4.64B |
| Orient EuroPharma | 4.59B |
| Panion & Bf Biotech | 2.11B |
| Orient Pharma | 1.52B |
| Easywell Biomedicals | 799.94M |
| Tien Liang BioTech | 650.87M |
| LIWANLI Innovation | 414.67M |